leisure time -WSS

leisure time

author：fashion 2025-09-28 11:20:52 - browse：84

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Stanford president faces new allegations over 1999 paper

WSS

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Stanford president faces new allegations over 1999 paper

Leading voice in opioid treatment defends methadone clinic system

Tocagen's brain cancer gene therapy trial continues. Investors worry

DeSantis talks Trump, trans issues and 'what wokeness is'

focus

leisure time

explore

Medical leaders decry Supreme Court decision on affirmative action

Plastic surgeons increase patient psychiatric screenings

Activists slam private health insurers over coverage restrictions

Colonoscopy prep: Liquid

Trump demands the U.S. pay no more for drugs than other countries … again

Texas Department of Public Safety speaks out on migrant abuse allegations

State Dept. review finds Biden bears some blame for Afghanistan failures

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Tori Bowie and the unacceptable rates of Black maternal death

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

focus

Stanford president's case begs question: Who takes blame?

Driven by the pandemic, applicants flood public health schools

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Study identifies new proteins linked to dementia risk 25 years later

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

knowledge

knowledge

focus

hotspot